Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 20/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 20/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 20/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924243 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL2828617 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Hydrochloric Acid SCHEMBL1925445 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Hydrochloric Acid SCHEMBL1926555 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL19856614 | 0.92 | CHRM3 (0.85) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL19856658 | 0.92 | CHRM2 (0.85) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL2830097 | 0.92 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5007157 | 0.92 | CHRM1 (0.92) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5007161 | 0.92 | CHRM1 (0.92) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL2829514 | 0.92 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345937-B1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-09-28 | — | — | EP | claimed |
| EP-1461336-B1 | 1-ALKYL-1-AZONIABICYCLO (2.2.2) OCTANE CARBAMATE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMA SPA (IT) | 2013-05-22 | — | — | EP | disclosed |
| EP-1300407-B2 | CARBAMATES DERIVED FROM ARYLALKYLAMINES | S A L V A T LAB SA (ES) | 2011-06-08 | — | — | EP | disclosed |
| US-7452904-B2 | 1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-11-18 | — | — | US | disclosed |
| US-7115629-B2 | quinuclidyl N-phenyl-N-alkyl carbamates used as muscarinic receptor antagonists, for prophylaxis of respiratory system, gastrointestinal and urogenital disorders | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-10-03 | — | — | US | disclosed |
| US-6916828-B2 | Carbamates derivatived from arylakylamines | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-07-12 | — | — | US | disclosed |
| US-20050043349-A1 | 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists | LABORATORIOS S.A.L.V.A.T. (ES) | 2005-02-24 | — | — | US | disclosed |
| US-20040235887-A1 | Carbamates derived from arylalkylamines | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-11-25 | — | — | US | disclosed |
| EP-1461336-A2 | 1-ALKYL-1-AZONIABICYCLO (2.2.2) OCTANE CARBAMATE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-09-29 | — | — | EP | disclosed |
| US-20040063950-A1 | Carbamates derivatived from arylakylamines | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-04-01 | — | — | US | disclosed |
| EP-1300407-B1 | CARBAMATES DERIVED FROM ARYLALKYLAMINES | S A L V A T LAB SA (ES) | 2004-02-25 | — | — | EP | disclosed |
| WO-2003053966-A2 | 1-ALKYL-1-AZONIABICYCLO [2.2.2] OCTANE CARBAMATE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2003-07-03 | — | — | WO | disclosed |
| EP-1300407-A1 | CARBAMATES DERIVED FROM ARYLALKYLAMINES | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235887-A1 | Carbamates derived from arylalkylamines | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
| US-20050043349-A1 | 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM2 1/4885CHRM1 3/4885CHRM3 2/4885 |
| US-20040063950-A1 | Carbamates derivatived from arylakylamines | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.